Merck KGaA’s Bavencio And Mavenclad Growth Steal Show During Q2 Earnings
With Double-Digit Growth
Sky-high sales growth of the German major’s Bavencio and Mavenclad caught the eye of some observers as the firm continues to advance these drugs in new disease settings to unlock their full potential.
You may also be interested in...
The firm’s BTK inhibitor tolebrutinib has been put on clinical hold by the US FDA following liver injuries, but advanced trials should continue as normal since most patients have passed the 60-day mark.
The German group's efforts in helping its peers in the industry with their respective COVID-19 vaccines have been rewarded with strong revenue growth while its own newer drugs beat analyst forecasts.
The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.